Solid Tumor: Clinical Trials

6 trials for Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed, 1 unknown. 6 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Recruiting 3, Completed 2, Unknown 1
Phase 22Recruiting 2

Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trop2-targeted immunoPET Imaging of Solid Tumors
[68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma
Phase 2 / Phase 3RecruitingRenJi Hospital4002024-12-232026-05-29
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
IAH0968, Trastuzumab Injection - Stomach Neoplasms, Solid Tumor
Phase 2 / Phase 3RecruitingSUNHO(China)BioPharmaceutical CO., Ltd.5742024-08-152026-06-05
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Pelabresib, Ruxolitinib - Hematologic Malignancy, Solid Tumor
Phase 3RecruitingNovartis Pharmaceuticals502024-08-132026-11-12
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
Onartuzumab, Bevacizumab, Erlotinib - Solid Tumor
Phase 3CompletedHoffmann-La Roche122015-08-272019-07-23
A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia
Eltrombopag, Placebo - Solid Tumor
Phase 3UnknownChang Gung Memorial Hospital832014-03-012017-10-24
Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device
cefazolin Sodium, placebo - Solid Tumor
Phase 3CompletedIstanbul University1502008-09-012010-06-02

Narrower conditions

Carcinoma, Transitional Cell (1)  ·  Cholangiocarcinoma (1)  ·  Endometrial Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Infections (1)  ·  Liver Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Nasopharyngeal Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Stomach Neoplasms (1)  ·  Thrombocytopenia (1)  ·  Thyroid Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Adenocarcinoma (1)  ·  Adnexal Diseases (1)  ·  Blood Platelet Disorders (1)  ·  Carcinoma (1)  ·  Cytopenia (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)

Interventions

Bevacizumab (1)  ·  CPI-0610 (1)  ·  Cefazolin (1)  ·  Erlotinib Hydrochloride (1)  ·  Trastuzumab (1)  ·  eltrombopag (1)  ·  onartuzumab (1)  ·  ruxolitinib (1)

Sponsors

Chang Gung Memorial Hospital (1)  ·  Hoffmann-La Roche (1)  ·  Istanbul University (1)  ·  Novartis Pharmaceuticals (1)  ·  RenJi Hospital (1)  ·  SUNHO(China)BioPharmaceutical CO., Ltd. (1)

Countries

China (2)  ·  Italy (2)  ·  Belgium (1)  ·  France (1)  ·  Japan (1)  ·  Latvia (1)  ·  Netherlands (1)  ·  Russia (1)  ·  Serbia (1)  ·  South Africa (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Hasan Karanlik, MD (1)  ·  Hung-Hsueh Chou (1)  ·  Jianjun Liu, Ph.D. & M.D. (1)  ·  Weijun Wei, Ph.D. & M.D. (1)

Results publications

PMID 21601826, PMID 41469668

NIH funding

2014 (1), 2023 (1)